Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study

B. Tombal, M. Borre, P. Rathenborg, P. Werbrouck, H. Van Poppel, A. Heidenreich, P. Iversen, J. Braeckman, J. Heracek, E. Baskin-Bey, T. Ouatas, F. Perabo, D. Phung, M. Hirmand, MR. Smith,

. 2014 ; 15 (6) : 592-600.

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu klinické zkoušky, fáze II, časopisecké články, multicentrická studie, Research Support, N.I.H., Extramural, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc14063660
E-zdroje Online Plný text

NLK ProQuest Central od 2000-09-01 do Před 2 měsíci
Nursing & Allied Health Database (ProQuest) od 2000-09-01 do Před 2 měsíci
Health & Medicine (ProQuest) od 2000-09-01 do Před 2 měsíci
Public Health Database (ProQuest) od 2000-09-01 do Před 2 měsíci

Odkazy

PubMed 24739897
DOI 10.1016/s1470-2045(14)70129-9
Knihovny.cz E-zdroje

BACKGROUND: The androgen receptor inhibitor enzalutamide is approved for the treatment of metastatic castration-resistant prostate cancer that has progressed on docetaxel. Our aim was to assess the activity and safety of enzalutamide monotherapy in men with hormone-naive prostate cancer. METHODS: This trial is an ongoing open-label, single-arm, phase 2 study, done across 12 European sites. Men aged over 18 years, with hormone-naive prostate cancer for whom hormone therapy was indicated, and who had non-castration levels of testosterone and prostate-specific antigen (PSA) of 2 ng/mL or greater at screening, and an Eastern Cooperative Oncology Group score of 0, received oral enzalutamide 160 mg/day. The primary outcome was the proportion of patients with an 80% or greater decline in PSA at week 25. All analyses included all patients who had received at least one dose of the study drug. This study is registered with ClinicalTrials.gov, number NCT01302041. FINDINGS: 67 men were enrolled into the study. 62 patients (92.5%, 95% CI 86.2-98.8) had a decline in PSA of 80% or greater at week 25. The most commonly reported treatment-emergent adverse events up to week 25 were gynaecomastia (n=24), fatigue (n=23), nipple pain (n=13), and hot flush (n=12), all of which were of mild to moderate severity. Nine patients had a treatment-emergent adverse event of grade 3 or higher, most of which were reported in one patient each, except for pneumonia (grade 3, two patients) and hypertension (grade 3, four patients). Five patients reported serious adverse events, none of which were deemed to be treatment related. INTERPRETATION: Our findings suggest that enzalutamide monotherapy in men with hormone-naive prostate cancer of varying severity provides a level of disease suppression, and was generally well tolerated. These findings provide a rationale for further investigation of clinical response and outcomes with enzalutamide in non-castrate men with prostate cancer.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc14063660
003      
CZ-PrNML
005      
20140708091617.0
007      
ta
008      
140704s2014 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/S1470-2045(14)70129-9 $2 doi
035    __
$a (PubMed)24739897
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Tombal, Bertrand $u Institut de Recherche Clinique, Université Catholique de Louvain, Brussels, Belgium. Electronic address: bertrand.tombal@uclouvain.be.
245    10
$a Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study / $c B. Tombal, M. Borre, P. Rathenborg, P. Werbrouck, H. Van Poppel, A. Heidenreich, P. Iversen, J. Braeckman, J. Heracek, E. Baskin-Bey, T. Ouatas, F. Perabo, D. Phung, M. Hirmand, MR. Smith,
520    9_
$a BACKGROUND: The androgen receptor inhibitor enzalutamide is approved for the treatment of metastatic castration-resistant prostate cancer that has progressed on docetaxel. Our aim was to assess the activity and safety of enzalutamide monotherapy in men with hormone-naive prostate cancer. METHODS: This trial is an ongoing open-label, single-arm, phase 2 study, done across 12 European sites. Men aged over 18 years, with hormone-naive prostate cancer for whom hormone therapy was indicated, and who had non-castration levels of testosterone and prostate-specific antigen (PSA) of 2 ng/mL or greater at screening, and an Eastern Cooperative Oncology Group score of 0, received oral enzalutamide 160 mg/day. The primary outcome was the proportion of patients with an 80% or greater decline in PSA at week 25. All analyses included all patients who had received at least one dose of the study drug. This study is registered with ClinicalTrials.gov, number NCT01302041. FINDINGS: 67 men were enrolled into the study. 62 patients (92.5%, 95% CI 86.2-98.8) had a decline in PSA of 80% or greater at week 25. The most commonly reported treatment-emergent adverse events up to week 25 were gynaecomastia (n=24), fatigue (n=23), nipple pain (n=13), and hot flush (n=12), all of which were of mild to moderate severity. Nine patients had a treatment-emergent adverse event of grade 3 or higher, most of which were reported in one patient each, except for pneumonia (grade 3, two patients) and hypertension (grade 3, four patients). Five patients reported serious adverse events, none of which were deemed to be treatment related. INTERPRETATION: Our findings suggest that enzalutamide monotherapy in men with hormone-naive prostate cancer of varying severity provides a level of disease suppression, and was generally well tolerated. These findings provide a rationale for further investigation of clinical response and outcomes with enzalutamide in non-castrate men with prostate cancer.
650    _2
$a adenokarcinom $x krev $x farmakoterapie $7 D000230
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a antagonisté androgenů $x terapeutické užití $7 D000726
650    _2
$a protinádorové látky $x terapeutické užití $7 D000970
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a fenylthiohydantoin $x analogy a deriváty $x terapeutické užití $7 D010669
650    _2
$a prostatický specifický antigen $x krev $7 D017430
650    _2
$a nádory prostaty $x krev $x farmakoterapie $7 D011471
650    _2
$a výsledek terapie $7 D016896
655    _2
$a klinické zkoušky, fáze II $7 D017427
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Borre, Michael $u Aarhus University Hospital, Aarhus, Denmark.
700    1_
$a Rathenborg, Per $u Herlev Hospital, Herlev, Denmark.
700    1_
$a Werbrouck, Patrick $u AZ Groeninge Kortrijk, Kortrijk, Belgium.
700    1_
$a Van Poppel, Hendrik $u UZ Leuven, Leuven, Belgium.
700    1_
$a Heidenreich, Axel $u Klinik und Poliklinik für Urologie, RWTH University Aachen, Aachen, Germany.
700    1_
$a Iversen, Peter $u Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
700    1_
$a Braeckman, Johan $u UZ Brussel, Brussels, Belgium.
700    1_
$a Heracek, Jiri $u Univerzita Karlova v Praze, Prague, Czech Republic.
700    1_
$a Baskin-Bey, Edwina $u Astellas Pharma Global Development, Leiden, Netherlands.
700    1_
$a Ouatas, Taoufik $u Astellas Pharma Global Development, Leiden, Netherlands.
700    1_
$a Perabo, Frank $u Astellas Pharma Global Development, Northbrook, IL, USA.
700    1_
$a Phung, De $u Astellas Pharma Global Development, Leiden, Netherlands.
700    1_
$a Hirmand, Mohammad $u Medivation Inc, San Francisco, CA, USA.
700    1_
$a Smith, Matthew R $u Massachusetts General Hospital Cancer Center, Boston, MA, USA.
773    0_
$w MED00011558 $t The lancet oncology $x 1474-5488 $g Roč. 15, č. 6 (2014), s. 592-600
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24739897 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20140704 $b ABA008
991    __
$a 20140708091907 $b ABA008
999    __
$a ok $b bmc $g 1031144 $s 862392
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 15 $c 6 $d 592-600 $i 1474-5488 $m Lancet oncology $n Lancet Oncol. $x MED00011558
LZP    __
$a Pubmed-20140704

Najít záznam

Citační ukazatele

Možnosti archivace